Press Releases

Admirals witnesses a significant rise in active and new clients.

Number of new applications in the Group went up by 77% to 266,779 applications compared to 2022 and is up by 116% compared to 2021. 

• The Group net trading income was 40.9 million (2022: EUR 69.0 million, 2021: EUR 35.7 million and 2020: EUR 62.2 million).
• EBITDA was EUR -6.5 million (2022: EUR 27.4 million, 2021: EUR 2.6 million and 2020: EUR 23.4 million).
• Number of active accounts in the Group... (continue reading...)

Tenth annual Scoops of Thanks Day features return of "How Now Brown Cow" Fresh Frozen Custard, benefits local FFA chapters

PRAIRIE DU SAC, Wis., April 30, 2024 /PRNewswire/ -- For the tenth straight year, Culver's is offering guests a single scoop of Fresh Frozen Custard in exchange for a $1 donation to local FFA chapters and other agricultural education organizations as part of its annual Scoops of Thanks Day fundraiser on May 2. This year's milestone event also... (continue reading...)

Laredo Oil (OTC: LRDC), an exploration and production company, today announced that the state of Montana issued to Hell Creek Crude LLC, a wholly owned subsidiary of Laredo Oil (“HCC”), a permit to drill the Reddig 11-21 well in the Midfork field located in Valley County, Montana. According to the announcement, this is the first of three production wells planned to be drilled and operated by HCC in the Midfork field. “This permit issuance now allows HCC to quickly... (continue reading...)

CALGARY, Alberta, April 30, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that further to its press release of March 11, 2024, the Company has received TSX Venture Exchange approval to amend the terms of an aggregate of 1,024,099 outstanding common... (continue reading...)

• Phase 2 clinical trial of temelimab against neuropsychiatric syndromes of Post-COVID (GNC-501):
  • Recruitment completed in November 2023;
  • Topline results planned for end of June 2024.

• Cash position of €2.8m as of December 31, 2023, including the €1m pre-financing of Research tax Credit received in January 2024
• Financial visibility into the third quarter of 2024 taking into account the €5m capital increase completed in Q1 2024

... (continue reading...)